PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17036319-11	2007	Further, activation of the EGFR-Akt pathway by taxane is related to this synergistic effect.	taxane	47-53	AKT serine/threonine kinase 1	Homo sapiens	32-35	
19240722-6	2009	An activated tumour cell VEGFR2/AKT/mTOR pathway was associated with increased incidence of ascites (chi(2), P=0.002) and reduced overall survival of cisplatin-taxane-based patients with serous histology (N=32, log-rank test, P=0.04).	taxane	160-166	AKT serine/threonine kinase 1	Homo sapiens	32-35	
17036319-8	2007	Regarding the mechanism of the synergistic effect, Western blotting analysis revealed that taxane activated the EGFR-Akt pathway in MCF7/ADR cells but not in MDA-MB-231.	taxane	91-97	AKT serine/threonine kinase 1	Homo sapiens	117-120	
34681173-8	2021	Mild antagonism was observed in combination with platinum- or taxane-based chemotherapy, which was putatively related to treatment-induced activation of p38, JNK1/2, ERK1/2, MEK1/2, and AKT, functioning as potential pro-survival factors.	taxane	62-68	AKT serine/threonine kinase 1	Homo sapiens	186-189	
35122700-1	2022	The phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently activated in HER2-negative breast cancer and may play a role in taxane resistance.	taxane	168-174	AKT serine/threonine kinase 1	Homo sapiens	41-44	
24062525-8	2013	RPPA data showed that VS-6063 reduced levels of AKT and YB-1 in taxane-resistant cell lines.	taxane	64-70	AKT serine/threonine kinase 1	Homo sapiens	48-51	
27196755-9	2016	These findings suggest that targeting Wnt/beta-catenin or Akt pathways may increase the efficacy of taxane chemotherapy in advanced human prostate cancers that have lost PKCdelta expression.	taxane	100-106	AKT serine/threonine kinase 1	Homo sapiens	58-61	
24062525-9	2013	FAK inhibition enhanced chemosensitivity in taxane-resistant cells by decreasing YB-1 phosphorylation and subsequently CD44 in an AKT-dependent manner.	taxane	44-50	AKT serine/threonine kinase 1	Homo sapiens	130-133	
22487539-1	2012	OBJECTIVES: On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer.	taxane	158-164	AKT serine/threonine kinase 1	Homo sapiens	115-118	
23535839-2	2013	Pre-clinical data support a link between PI3 K/AKT signalling and taxane resistance.	taxane	66-72	AKT serine/threonine kinase 1	Homo sapiens	47-50	
23535839-3	2013	Using the UK taxotere as adjuvant chemotherapy trial (TACT), we tested the hypothesis that activation of AKT or downstream markers, p70S6K or p90RSK, identifies patients with reduced benefit from taxane chemotherapy.	taxane	196-202	AKT serine/threonine kinase 1	Homo sapiens	105-108	
22895534-7	2012	In conclusion, these data suggest that NEP can augment taxane-induced apoptosis through inhibition of Akt/Bad signaling, and that the combination of NEP plus paclitaxel may be an effective strategy to inhibit castration-resistant prostate cancer growth.	taxane	55-61	AKT serine/threonine kinase 1	Homo sapiens	102-105	
23408298-1	2013	BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy.	taxane	253-259	AKT serine/threonine kinase 1	Homo sapiens	67-70